二代整合酶抑制剂两药和三药方案一线或二线HIV-1学性失败时新发耐药相关突变:Virostar-1研究
Virostar-1研究基于法国多中心数据库回顾性分析2019至2022年间接受比克替拉韦/恩曲他滨/丙酚替诺福韦、多替拉韦/阿巴卡韦/拉米夫定、多替拉韦/拉米夫定或多替拉韦/利匹韦林方案且发生一线或二线学性失败的HIV感染者,在失败时检测基因型耐药。总体学性失败率低,新发整合酶或核苷类逆转录酶抑制剂耐药突变率分别为4%、8.5%、18%和39%新发非核苷类逆转录酶抑制剂耐药突变,但未观察到对核苷类逆转录酶抑制剂和整合酶抑制剂的完全双重耐药。
要点
- 比克替拉韦/恩曲他滨/丙酚替诺福韦方案学性失败率6.8%,新发整合酶或核苷类逆转录酶抑制剂耐药突变率4%。
- 多替拉韦/阿巴卡韦/拉米夫定方案学性失败率7.5%,新发整合酶或核苷类逆转录酶抑制剂耐药突变率8.5%。
- 多替拉韦/拉米夫定方案学性失败率5.1%,新发整合酶或核苷类逆转录酶抑制剂耐药突变率18%;多替拉韦/利匹韦林方案学性失败率2.1%,新发非核苷类逆转录酶抑制剂耐药突变率39%。
核心结论
- 在发生多替拉韦或比克替拉韦方案一线或二线学性失败的HIV感染者中,罕见新发整合酶抑制剂耐药突变,新发核苷类逆转录酶抑制剂耐药突变也较少。
- 观察到的学性失败时新发耐药突变率分别为比克替拉韦/恩曲他滨/丙酚替诺福韦4%、多替拉韦/阿巴卡韦/拉米夫定8.5%、多替拉韦/拉米夫定18%和多替拉韦/利匹韦林39%。
研究设计与样本
- Virostar-1研究为回顾性分析,基于法国多中心数据库,分析2019至2022年间发生一线或二线学性失败时检测的基因型耐药。
- 学性失败定义为连续两次HIV-1血浆病毒载量>50拷贝/mL,学性失败时采用Sanger法检测,耐药突变按ANRS算法报告。
- 研究期间共随访5986例HIV感染者,接受一线或二线治疗。
主要发现
- 学性失败率总体较低:比克替拉韦/恩曲他滨/丙酚替诺福韦6.8%,多替拉韦/阿巴卡韦/拉米夫定7.5%,多替拉韦/拉米夫定5.1%,多替拉韦/利匹韦林2.1%。
- 新发整合酶或核苷类逆转录酶抑制剂耐药突变率:比克替拉韦/恩曲他滨/丙酚替诺福韦4%,多替拉韦/阿巴卡韦/拉米夫定8.5%,多替拉韦/拉米夫定18%;多替拉韦/利匹韦林新发非核苷类逆转录酶抑制剂耐药突变率39%。
- 未观察到对核苷类逆转录酶抑制剂和整合酶抑制剂的完全双重耐药。
关键数值与推荐
- 学性失败定义:连续两次HIV-1血浆病毒载量>50拷贝/mL。
- 耐药突变检测方法:Sanger法,按ANRS算法报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 选择偏倚使得无法进行组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens. OBJECTIVES: The Virostar-1 study objective is to analyse the emergence of resistance-associated mutations (RAMs) over 3 years with DTG-based 2DRs and DTG- or bictegravir (BIC)-based 3DRs in people living with HIV (PLWH) experiencing a VF (FL or SL). METHODS: Retrospective analysis of genotypic resistance detected at the time of a FL or SL VF with BIC/FTC/TAF, DTG/ABC/3TC, DTG/3TC and DTG/RPV between 2019 and 2022 was conducted from a French multicentre database. VF was defined as two consecutive HIV-1 plasma viral loads > 50 c/mL. Sanger assays were performed at VF within standard clinical care. Resistance mutations were reported using the ANRS algorithm. Selection biases prevent group comparisons. RESULTS: During the period, N = 5986 PLWH were followed either in FL or SL. The VF rate was overall low: BIC/FTC/TAF, 6.8%; DTG/ABC/3TC, 7.5%; DTG/3TC, 5.1%; and DTG/RPV, 2.1%. Some emergent InSTI or NRTI RAMs were detected with BIC/FTC/TAF 4%, DTG/ABC/3TC 8.5%, DTG/3TC 18% and 39% emergent NNRTI RAMs with DTG/RPV. However, a complete absence of dual resistance against NRTIs and InSTIs was observed. CONCLUSIONS: We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.
引用
- Marcelin AG, Soulie C, Wirden M, et al. Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. J Antimicrob Chemother. 2025. PMID: 39436753. doi:10.1093/jac/dkae377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。